Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia

•A case of extensively drug-resistant Acinetobacter baumannii bacteremia in an immunocompetent infant is reported.•Tigecycline was used successfully with monitoring of trough serum concentrations to address its safety, efficacy, and pharmacokinetics.•This is the first report of tigecycline monitoring in a pediatric patient with bloodstream infection​, and it is worth monitoring drug concentrations.•This is the youngest case treated with tigecycline for A. baumannii bacteremia according to the published literature.•Tigecycline can be given for life-threatening infections in children for whom no better alternative antimicrobial options are available.

SummaryThe successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented. Tigecycline serum concentrations were monitored to help improve antibiotic efficacy and minimize side effects. A literature review identified 11 additional pediatric cases of A. baumannii infection treated with tigecycline since 2011. Tigecycline treatment should be considered in children with extensively drug-resistant bacterial infections.